This, coupled with the fact that visitor numbers are capped by the drna
and there is no timetabled transport, lends Mona an ambivalent and remote character.
, 2004) and Section 402(b) of the Magnuson-Stevens Fishery Conservation and Management Act (NMFS, 2007).
) (the 'Company' or 'Dicerna'), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial results for the second quarter ended June 30, 2019 and provided a corporate update.
Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA
) and Bluebird Bio (BLUE).
* Dicerna Pharmaceuticals Inc (NASDAQ: DRNA
) shares gained 7.8 percent to $6.08.
) (the 'Company' or 'Dicerna'), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 218,500 shares of common stock to be distributed among six new employees, with a grant date of August 1, 2019 (the 'Inducement Grant').
) has released updated data from its ongoing PHYOX1 Phase 1 clinical trial evaluating DCR-PHXC, the company's lead GalXC product candidate, the company said.
), up 26% after the company and Eli Lilly (LLY) announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain...